Acacia Pharma Ltd.
- Country
- 🇬🇧United Kingdom
- Ownership
- Subsidiary
- Established
- 2006-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.acaciapharma.com
Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients
- Conditions
- Nausea and Vomiting, Postoperative
- Interventions
- First Posted Date
- 2022-09-19
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Acacia Pharma Ltd
- Target Recruit Count
- 410
- Registration Number
- NCT05546359
- Locations
- 🇫🇷
HCL - Hôpital Mère Enfant, Bron, France
🇩🇪Universitätsklinikum Würzburg, Würzburg, Bayern, Germany
🇺🇸UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
Post Operative Nausea and Vomiting (PONV) Rescue Outcomes After Amisulpride Treatment
- Conditions
- Nausea and Vomiting, Postoperative
- Interventions
- Drug: Rescue Post-Operative Nausea and Vomiting (PONV) treatment according to the standard of care (SOC)
- First Posted Date
- 2021-07-08
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Acacia Pharma Ltd
- Registration Number
- NCT04954365
Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures
- First Posted Date
- 2021-04-20
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- Acacia Pharma Ltd
- Target Recruit Count
- 100
- Registration Number
- NCT04851717
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇩🇰Odense Universitetshospital, Odense, Denmark
🇺🇸Stanford University, Palo Alto, California, United States
PK Study of IV and Oral Amisulpride in Subjects With Severe Renal Impairment
- Conditions
- Renal Disease, End Stage
- Interventions
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- Acacia Pharma Ltd
- Target Recruit Count
- 12
- Registration Number
- NCT04849650
- Locations
- 🇺🇸
Panax Clinical Research, Miami Lakes, Florida, United States
Study of APD421 With and Without Ondansetron
- Conditions
- Postoperative Nausea and Vomiting
- Interventions
- First Posted Date
- 2018-07-11
- Last Posted Date
- 2018-10-01
- Lead Sponsor
- Acacia Pharma Ltd
- Target Recruit Count
- 30
- Registration Number
- NCT03583489
- Locations
- 🇬🇧
Early Phase Clinical Unit, London, United Kingdom
Mass-balance Study of [14C]-APD421 in Healthy Volunteers
- Conditions
- Post-operative Nausea and Vomiting
- Interventions
- Drug: 14C-APD421
- First Posted Date
- 2016-08-29
- Last Posted Date
- 2019-06-25
- Lead Sponsor
- Acacia Pharma Ltd
- Target Recruit Count
- 6
- Registration Number
- NCT02881840
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
Thorough QT Study of Intravenous Amisulpride
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2016-01-22
- Last Posted Date
- 2018-11-29
- Lead Sponsor
- Acacia Pharma Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT02661594
Study of APD421 as PONV Treatment (Prior Prophylaxis)
- First Posted Date
- 2016-01-05
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- Acacia Pharma Ltd
- Target Recruit Count
- 705
- Registration Number
- NCT02646566
- Locations
- 🇩🇪
HELIOS Klinikum Aue, Aue, Germany
🇺🇸Jackson Memorial Hospital, Miami, Florida, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
Study of APD421 as PONV Treatment (no Prior Prophylaxis)
- First Posted Date
- 2015-05-20
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- Acacia Pharma Ltd
- Target Recruit Count
- 568
- Registration Number
- NCT02449291
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸Jackson Memorial Hospital, Miami, Florida, United States
🇫🇷CHU de Hautepierre, Strasbourg, France
Phase IIIb Study of APD421 in Combination as PONV Prophylaxis
- First Posted Date
- 2015-01-13
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Acacia Pharma Ltd
- Target Recruit Count
- 1147
- Registration Number
- NCT02337062
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸Stony Brook Medicine, Stony Brook, New York, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States